Prevention of influenza complications in patients with liver disease: a retrospective cohort study

Front Public Health. 2023 Dec 20:11:1288126. doi: 10.3389/fpubh.2023.1288126. eCollection 2023.

Abstract

Introduction: Patients with chronic liver disease are highly prone to acquiring influenza infection diseases and experiencing associated complications. National and international guidelines recommend the influenza vaccine for patients with liver disorders to reduce the risk of influenza complications. Our study aims to evaluate the risk of flu complications faced by patients with liver disease and assess influenza vaccination coverage.

Methods: The archive of hospital discharge forms was used to define the list of Apulian patients with liver disease, considering data from 2017 through 2022. The vaccination status of these patients was assessed via data collected from the Regional Immunization Database. We focused on influenza vaccine shots administered during the 2020/21, 2021/22, and 2022/23 flu seasons.

Results: A declining trend across the flu seasons was observed, with a VC of 49.5% in the 2020/21 flu season, 48.1% in the 2021/22 season, and 45.0% in the 2022/23 season. Subjects with multiple comorbidities have higher vaccination rates. Additionally, the multivariate models demonstrate that vaccination compliance increases with age and is strongly associated with having received a previous influenza vaccine shot.

Conclusion: The VC rates reported in our study are unsatisfactory and did not reach the minimum achievable goal (75%) the Italian Ministry of Health set. A multifactorial approach is required to raise the immunization rates and therefore protect the patients from the influenza-associated risk of collateral liver damage; the role of gastroenterologists and hepatologists is crucial, as their responsibilities should extend beyond patient care to the prevention of complications after infectious diseases.

Keywords: cirrhosis; gastroenterology; infectious diseases; influenza; public health.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Influenza Vaccines*
  • Influenza, Human* / complications
  • Influenza, Human* / prevention & control
  • Liver Diseases* / complications
  • Retrospective Studies
  • Vaccination

Substances

  • Influenza Vaccines

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Italian Ministry of Health: RC2023.